GenVec to Present at the ROTH 22nd Annual Orange County Growth Stock Conference

GAITHERSBURG, Md., March 9 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) today announced that Douglas J. Swirsky, Senior Vice President and Chief Financial Officer, will present a company overview highlighting recent developments at the ROTH 22nd Annual Orange County Growth Stock Conference on Tuesday, March 16, 2010 at 10:00 a.m. PDT at the Ritz Carlton Laguna Niguel in Dana Point, CA.

A webcast of Mr. Swirsky's presentation will be available both live and on replay.  To access either the live or archived webcast, log on to GenVec's website at www.genvec.com, click on "Investor Relations," and proceed to "Webcasts & Data."  The replay will be available 24 hours after the live presentation and will be accessible for 30 days.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. In addition, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel treatments for hearing loss and balance disorders through a worldwide collaboration with Novartis. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

SOURCE GenVec, Inc.